代謝體學市場規模、佔有率、成長分析、按產品、按生物資訊學工具和服務、按應用、按適應症、按最終用戶、按公司類型、按地區 - 2025 年至 2032 年行業預測

2023 年代謝體學市場規模價值為 41 億美元，預計將從 2024 年的 46.7 億美元成長到 2032 年的 131.2 億美元，預測期內（2025-2032 年）的複合年成長率為 13.8%。

由於代謝組學在精準醫療中的應用日益廣泛以及慢性病診斷方法的不斷發展，代謝體學市場預計將顯著成長。主要促進因素包括製藥領域研發投入的增加和分析技術的進步，特別是核磁共振波譜和質譜技術，使得能夠對各種生物樣本中的代謝物進行全面的分析。這種複雜性將有助於更好地了解與糖尿病、心臟病和癌症等疾病相關的代謝異常。透過揭示個體的代謝特徵，代謝體學可以促進個體化醫療，從而實現更好的疾病預測和個人化的管理策略。隨著研究發現新的代謝物和相互作用，對標靶和非標靶代謝體學服務的需求將會增加，鞏固代謝體學在醫療保健創新中的重要性。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

代謝體學市場規模（按產品和複合年成長率） (2025-2032)

• 市場概況
• 代謝體學學儀器
• 隔離工具
  • 氣相層析法
  • 高效液相層析
  • 超高效液相層析
  • 毛細管電泳
• 發現工具
  • 核磁共振（NMR）光譜
  • 質譜法（MS）
  • 基於表面的質譜分析

代謝體學市場規模（依生物資訊工具及服務分類）及複合年成長率（2025-2032）

• 市場概況
• 生物資訊服務
• 生物資訊工具和資料庫

代謝體學市場規模（按應用和複合年成長率） (2025-2032)

• 市場概況
• 生物標記發現
• 藥物研發
• 毒性測試
• 營養基因體學
• 功能基因體學
• 個人化醫療
• 其他用途

代謝體學市場規模（按適應症和複合年成長率） (2025-2032)

• 市場概況
• 癌症
• 心血管疾病
• 神經系統疾病
• 代謝紊亂
• 先天性代謝缺陷
• 其他適應症

代謝體學市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 學術研究所
• 製藥和生物技術公司
• 合約研究組織
• 其他最終用戶

代謝體學市場規模（按公司類型和複合年成長率） (2025-2032)

• 市場概況
• 層級製藥公司
• 層級製藥公司
• 層級製藥公司

代謝體學市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Agilent Technologies, Inc.（US）
• Thermo Fisher Scientific, Inc.（US）
• Waters Corporation（US）
• Bruker Corporation（US）
• Shimadzu Corporation（Japan）
• Danaher Corporation（SCIEX）（US）
• PerkinElmer, Inc.（US）
• Merck KGaA（Germany）
• Bio-Rad Laboratories, Inc.（US）
• Metabolon, Inc.（US）
• LECO Corporation（US）
• Human Metabolome Technologies, Inc.（Japan）
• GL Sciences, Inc.（Japan）
• Bioocrates Life Sciences AG（Austria）
• BASF SE（Germany）
• MS-OMICS（Various locations）
• Afekta Technologies Ltd.（Finland）
• DNA Xperts Private Limited.（India）
• Metabolomic Technologies Inc.（Canada）
• Kore Technology Ltd.（UK）

結論和建議

Metabolomics Market size was valued at USD 4.1 billion in 2023 and is poised to grow from USD 4.67 billion in 2024 to USD 13.12 billion by 2032, growing at a CAGR of 13.8% during the forecast period (2025-2032).

The metabolomics market is poised for significant growth due to its increasing adoption in precision medicine and evolving diagnostics for chronic conditions. Key drivers include rising R&D investments in the pharmaceutical sector and advancements in analytical techniques, particularly nuclear magnetic resonance spectroscopy and mass spectrometry, which enable the comprehensive analysis of metabolites in various biological samples. This sophistication enhances our understanding of metabolic dysregulation associated with diseases like diabetes, heart disease, and cancer. By revealing individual metabolic signatures, metabolomics facilitates tailored medical care, enabling better disease prediction and personalized management strategies. As research uncovers novel metabolites and interactions, the demand for targeted and untargeted metabolomics services is set to rise, solidifying its importance in healthcare innovation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Metabolomics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Metabolomics Market Segments Analysis

Global Metabolomics Market is segmented by Product, Bioinformatics Tools and Services, Application, Indication, End User, Company Type and region. Based on Product, the market is segmented into Metabolomics Instruments, Separation Tools and Detection Tools. Based on Bioinformatics Tools and Services, the market is segmented into Bioinformatics Services and Bioinformatics Tools and Databases. Based on Application, the market is segmented into Biomarker discovery, Drug discovery, Toxicology testing, Nutrigenomics, Functional Genomics, Personalized medicine and Other Applications. Based on Indication, the market is segmented into Cancer, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders, Inborn Errors of Metabolism and Other Indications. Based on End User, the market is segmented into Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End Users. Based on Company Type, the market is segmented into Tier 1 Pharmaceutical Companies, Tier 2 Pharmaceutical Companies and Tier 3 Pharmaceutical Companies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Metabolomics Market

Metabolite profiling within biological matrices plays a crucial role in discovering biomarkers and advancing personalized medicine. Through metabolomics studies, researchers can identify various biomarkers associated with intricate clinical phenotypes across multiple biological systems. This process is instrumental in the development of tailored medical treatments, focusing on optimizing therapeutic effectiveness while addressing potential toxicity issues. By employing metabolomics, healthcare providers can enhance patient outcomes by ensuring that medical interventions are more aligned with individual biological responses, ultimately paving the way for a more personalized approach to healthcare.

Restraints in the Metabolomics Market

The Metabolomics market faces significant restraints due to the rapid increase in high-volume and heterogeneous data generation, which exacerbates the existing complexity surrounding data management. As life science research produces increasingly intricate and multifaceted data, accurately evaluating high-dimensional information becomes a daunting challenge. This heightened complexity is anticipated to hinder the growth of the Metabolomics market, as researchers and organizations struggle to effectively analyze and interpret the data generated. Consequently, the difficulty in managing such complicated datasets may limit advancements and adoption within the sector, ultimately restraining its potential expansion and innovation.

Market Trends of the Metabolomics Market

The Metabolomics market is witnessing a significant upward trend driven by the expanding applications of biomarkers derived from bioinformatics analyses. As healthcare increasingly pivots towards personalized medicine, the identification of novel biomarkers through metabolomics advancements is becoming essential for in-vitro diagnostics, environmental toxicology assessment, and drug discovery processes. Over the past decade, the "omics" revolution has not only enhanced the technical capabilities of metabolomics but also broadened its relevance across various biomedical domains. This growth trajectory is expected to continue, fueled by the rising demand for precision medicine and integrative approaches to health diagnostics, propelling the Metabolomics market into new horizons of innovation and application.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Metabolomics Market Size by Product & Service & CAGR (2025-2032)

• Market Overview
• Metabolomics Instruments
• Separation Tools
  • Gas Chromatography
  • High-performance Liquid Chromatography
  • Ultra-performance Liquid Chromatography
  • Capillary Electrophoresis
• Detection Tools
  • Nuclear Magnetic Resonance (NMR) Spectroscopy
  • Mass Spectrometry (MS)
  • Surface-Based Mass Analysis

Global Metabolomics Market Size by Bioinformatics Tools and Services & CAGR (2025-2032)

• Market Overview
• Bioinformatics Services
• Bioinformatics Tools and Databases

Global Metabolomics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Biomarker discovery
• Drug discovery
• Toxicology testing
• Nutrigenomics
• Functional Genomics
• Personalized medicine
• Other Applications

Global Metabolomics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Metabolic Disorders
• Inborn Errors of Metabolism
• Other Indications

Global Metabolomics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Academic and Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Other End Users

Global Metabolomics Market Size by Company Type & CAGR (2025-2032)

• Market Overview
• Tier 1 Pharmaceutical Companies
• Tier 2 Pharmaceutical Companies
• Tier 3 Pharmaceutical Companies

Global Metabolomics Market Size & CAGR (2025-2032)

• North America (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
  • US
  • Canada
• Europe (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Waters Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bruker Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shimadzu Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (SCIEX) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolon, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LECO Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Human Metabolome Technologies, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GL Sciences, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioocrates Life Sciences AG (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BASF SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MS-OMICS (Various locations)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Afekta Technologies Ltd. (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DNA Xperts Private Limited. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolomic Technologies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kore Technology Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations